Back to News
Market Impact: 0.22
Optimi Health Plans Phase 3 Trial Of MDMA-Assisted Therapy For PTSD
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Optimi Health plans to begin a Health Canada-authorized Phase 3 trial of synthetic MDMA-assisted therapy for PTSD in 2027. The authorization advances the company's clinical-development pathway, but the long timeline and absence of efficacy or financial data limit the near-term impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
OPTH0.45
More News
- Congress passes sweeping US sanctions bill targeting Russia
- House Passes Bill Allowing Trump Tariffs on Russian Oil Buyers
- Fed Rate Hike Looms as Retail Sales Surge
- The Fed decision, Clarity Act fails in Senate, Ford's truck prices and more in Morning Squawk
- OpenAI discloses six more instances of ’concerning’ AI model behavior
- House set to pass sweeping Russia sanctions bill honoring Lindsey Graham